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Background
We previously reported an anti-CD20-interferon-alpha
(IFNa) fusion protein able to induce apoptosis and
promote in vivo eradication of a human CD20-
expressing mouse B cell lymphoma [Xuan et al, Blood
2010]. We now report the activity of a recombinant
anti-CD20-human IFNa fusion protein against human
non-Hodgkin B cell lymphomas (NHL).
Methods
Anti-CD20-hIFNa was evaluated against a panel of human
Burkitt, diffuse large B cell (DLBCL), and mantle cell
lymphoma cell lines. Proliferation was measured by
[3H]-thymidine, complement-dependent cytotoxicity
(CDC) by PI flow cytometry, and antibody-dependent
cellular cytotoxicity (ADCC) by LDH release using PBMC
effectors. NHL xenografts were grown in SCID mice.
Results
Anti-CD20-hIFNa induced stronger growth inhibition
than rituximab, particularly against Burkitt and germinal
center-type DLBCL NHLs. Tumor growth inhibition by
anti-CD20-hIFNa was associated with substantial apopto-
sis in some cell lines. Anti-CD20-hIFNa exhibited potent
ADCC activity against Daudi, Ramos, and Raji cells, identi-
cal to rituximab. Surprisingly, anti-CD20-hIFNa exhibited
superior CDC compared to rituximab against Daudi,
Ramos, and Raji cells that was dependent upon linkage of
IFNa to the anti-CD20 antibody, and correlated with
improved complement fixation. Importantly, against Raji
NHL xenograft tumors in SCID mice, anti-CD20-hIFNa
achieved superior efficacy compared to rituximab
(p=0.0015) and control fusion protein (p<0.0001). At anti-
body doses at which Raji xenograft tumors progressed
through rituximab, anti-CD20-hIFNa eradicated 50-88%
of established tumors. Non-targeted control fusion protein
had only minor effects on tumor growth.
Conclusions
Anti-CD20-hIFNa has stronger direct anti-proliferative
and CDC activities than rituximab against human NHL
while retaining potent ADCC activity, and also has the
ability to eradicate established NHL xenografts in vivo.
These results support the further development of anti-
CD20-hIFNa for the treatment of B cell NHL, and a phase
I first-in-human clinical trial is currently being planned.
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